Nov 10,2022

Tandem Diabetes Care Study Demonstrates Improvements of All Clinical Endpoints in Adults with Type 2 Diabetes Using Control-IQ Technology

Tandem Diabetes Care, Inc., a leading insulin delivery and diabetes technology company, announced results from a prospective, multicenter, single-arm study of adults living with type 2 diabetes who achieved improvement in all clinical endpoints with the use of the t:slim X2 insulin pump with Control-IQ technology.

CLINICAL STUDY

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Jan 19,2022

Kaia Health Digital Therapeutic Study Suggests High Safety Level

Kaia Health announces results of a comprehensive safety study of its musculoskeletal (MSK) digital therapeutic. In the study population, fewer than 1% of Kaia Health MSK solution users reported any adverse events (AEs). Additionally, no relationship between gender and the reporting of adverse events was found. Published in the peer-reviewed JMIR Human Factors, the study evaluated the safety profile of the Kaia Health MSK solution by performing a comprehensive assessment of reported AEs by nearly 140,000 users. Study authors reported that AEs involving Kaia Health’s digital therapy were consistent with those reported for in-person therapies for low back pain.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jan 20,2022

Theranica Publishes Largest Ever Real-World Study of a Migraine Device

Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, announced today the publication of a new peer-reviewed study analyzing the efficacy, safety and sustainability of remote electrical neuromodulation (REN) as a standalone, and medication adjunct, treatment of migraine. Out of 2,514 patients included in the efficacy analysis, 32% of the episodic migraine patients and 21% of the chronic migraine patients, achieved pain freedom two hours post treatment in most of their treatments, and over 65% experienced sustained pain relief post two hours.

CLINICAL STUDY

#connected device

#pdt

View Analyst & Ambassador Comments
Go to original news
Jan 25,2022

Medication adherence doubles when patients use digital health apps

In a study recently published in Nature’s Scientific Reports, Propeller Health found that controller medication adherence among patients with chronic respiratory disease was more likely to increase (up to twofold) with digital health app engagement. Data was collected from a study group that included 1,629 participants with asthma and 663 participants with COPD who were using the Propeller platform.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Feb 02,2022

Patients Receiving Virta’s Diabetes Reversal Treatment See Sustained Reduction in Depressive Symptoms, New Research Shows

Virta Health, the leader in type 2 diabetes reversal, announced promising results on the impact of its diabetes reversal treatment on depressive symptoms. The research, published in The Journal of Behavioral Medicine, highlights rapid and sustained improvement in depressive symptoms during treatment, with nearly one-third fewer patients meeting the clinical cutoff for depression at two years.

CLINICAL STUDY

#telehealth

#virtual care

View Analyst & Ambassador Comments
Go to original news
Feb 04,2022

Characteristics of Mobile Health Platforms for Depression and Anxiety: Content Analysis Through a Systematic Review of the Literature and Systematic Search of Two App Stores

Mobile health (mHealth) platforms show promise in the management of mental health conditions such as anxiety and depression. This has resulted in an abundance of mHealth platforms available for research or commercial use. The objective of this review is to characterize the current state of mHealth platforms designed for anxiety or depression that are available for research, commercial use, or both.

CLINICAL STUDY

#mobile app

#cbt

View Analyst & Ambassador Comments
Go to original news
Feb 07,2022

Independent validation shows Hello Heart can save employers an average of $1,865 per patient

Validation Institute confirms study findings that Hello Heart ’s AI-driven, smartphone-based solution saves employers an average of $1,865 per year for each participant who used Hello Heart by reducing trips to the ER, emergency surgeries, and imaging diagnostics.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Feb 15,2022

Effects on Adherence to a Mobile App–Based Self-management Digital Therapeutics Among Patients With Coronary Heart Disease: Pilot Randomized Controlled Trial

The adherence to secondary prevention treatment in patients with coronary heart disease (CHD) is low. Digital therapeutics (DTx) refers to an emerging branch of medicine that delivers medical interventions directly to patients using evidence-based, clinically evaluated, technology-based software algorithms or apps to facilitate disease management, which may be an efficient tool to optimize adherence. This paper aims to investigate the effect of mobile app–based self-management DTx on long-term use of secondary prevention medications in patients with CHD in China.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Feb 16,2022

Peer-Reviewed Study Shows Positive Impact of Nerivio’s® Guided Imagery, Education and Relaxation (GIER) Feature on Migraine Treatment Response

Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, today announced the publication of a new peer-reviewed study published in Pain Medicine, examining the use of combining Nerivio's® Guided Imagery, Education and Relaxation (GIER) in-app optional behavioral intervention feature for acute treatment of migraine. One group used Nerivio, a wearable migraine therapeutic, by itself. The other Nerivio+GIER group supplemented Nerivio treatments with the new GIER feature. Results from the match-controlled, dual-arm study indicate the Nerivio+GIER group had a higher proportion of patients achieving consistent pain relief, consistent improvement in functioning, and consistent return to normal functioning, beyond that of Nerivio treatment alone.

CLINICAL STUDY

#pdt

#connected device

View Analyst & Ambassador Comments
Go to original news
Feb 17,2022

PLOS ONE Publishes Clinical Study Results and EEG Data Showing Akili Digital Therapeutic EndeavorRx® Activates Systems in Brain Key to Attentional Functioning

The study measured electroencephalography (EEG) data alongside behavioral and clinical metrics of attention in children with ADHD using AKL-T01 (EndeavorRx). Data from the study show that EndeavorRx treatment resulted in increased brain activity related to attention function, as measured by EEG, which correlated with improvements in objective behavioral measures of attention. The study results were published in the medical journal PLOS ONE.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Subscribe to CLINICAL STUDY